TREVI THERAPEUTICS INC (TRVI)
US89532M1018 - Common Stock
We assign a fundamental rating of 3 out of 10 to TRVI. TRVI was compared to 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for TRVI as it has an excellent financial health rating, but there are worries on the profitability. TRVI has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year TRVI has reported negative net income.
TRVI had a negative operating cash flow in the past year.
In the past 5 years TRVI always reported negative net income.
TRVI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -64.31%, TRVI is doing worse than 67.39% of the companies in the same industry.
Looking at the Return On Equity, with a value of -75.15%, TRVI is in line with its industry, outperforming 47.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.31% | ||
| ROE | -75.15% | ||
| ROIC | N/A |
ROA(3y)-48.12%
ROA(5y)-51.7%
ROE(3y)-86.94%
ROE(5y)-85.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TRVI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for TRVI has been increased compared to 1 year ago.
The number of shares outstanding for TRVI has been increased compared to 5 years ago.
Compared to 1 year ago, TRVI has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 14.71 indicates that TRVI is not in any danger for bankruptcy at the moment.
TRVI has a Altman-Z score of 14.71. This is amongst the best in the industry. TRVI outperforms 90.22% of its industry peers.
There is no outstanding debt for TRVI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 14.71 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 7.38 indicates that TRVI has no problem at all paying its short term obligations.
TRVI has a Current ratio of 7.38. This is in the better half of the industry: TRVI outperforms 78.26% of its industry peers.
A Quick Ratio of 7.38 indicates that TRVI has no problem at all paying its short term obligations.
TRVI has a better Quick ratio (7.38) than 79.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.38 | ||
| Quick Ratio | 7.38 |
3. Growth
3.1 Past
TRVI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -62.96%.
EPS 1Y (TTM)-62.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 18.58% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-71.8%
EPS Next 2Y-30.68%
EPS Next 3Y-22.1%
EPS Next 5Y18.58%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
TRVI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TRVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as TRVI's earnings are expected to decrease with -22.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.68%
EPS Next 3Y-22.1%
5. Dividend
5.1 Amount
TRVI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TREVI THERAPEUTICS INC
NASDAQ:TRVI (1/7/2025, 8:16:14 PM)
After market: 4.07 0 (0%)4.07
-0.25 (-5.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners67.08%
Inst Owner Change0%
Ins Owners1.25%
Ins Owner Change0.1%
Market Cap357.96M
Analysts85.33
Price Target9.58 (135.38%)
Short Float %7.15%
Short Ratio2.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.3%
Min EPS beat(2)-10.99%
Max EPS beat(2)-7.61%
EPS beat(4)1
Avg EPS beat(4)-6.68%
Min EPS beat(4)-22.55%
Max EPS beat(4)14.44%
EPS beat(8)5
Avg EPS beat(8)8.85%
EPS beat(12)9
Avg EPS beat(12)11.22%
EPS beat(16)11
Avg EPS beat(16)9.77%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.05%
PT rev (3m)3.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.13%
EPS NY rev (1m)0.22%
EPS NY rev (3m)-4.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.07 | ||
| P/tB | 6.07 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0
BVpS0.67
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.31% | ||
| ROE | -75.15% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-48.12%
ROA(5y)-51.7%
ROE(3y)-86.94%
ROE(5y)-85.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 31.69% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.38 | ||
| Quick Ratio | 7.38 | ||
| Altman-Z | 14.71 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)170.46%
Cap/Depr(5y)119.28%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.5%
EPS Next Y-71.8%
EPS Next 2Y-30.68%
EPS Next 3Y-22.1%
EPS Next 5Y18.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-52.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-52.22%
EBIT Next 3Y-34.65%
EBIT Next 5Y17.92%
FCF growth 1Y-24.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.92%
OCF growth 3YN/A
OCF growth 5YN/A